Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance

Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance


Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021.

Source: NYSE

Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations for revenue and offered rosy guidance.

Here’s how the company did:

  • Earnings per share: 37 cents, may not compare with the 34 cents expected by LSEG
  • Revenue: $168.6 million vs. $152.8 million expected by LSEG

Doximity is a digital platform for medical professionals that helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. The company primarily generates revenue through its telehealth tools, hiring solutions and marketing offerings for clients such as pharmaceutical companies.

Doximity’s revenue increased 25% in its third quarter from $135.3 million during the same period last year, according to a release.

For its fiscal fourth quarter, Doximity said it expects to report revenue between $132.5 million and $133.5 million, compared with analysts’ estimates of $123.8 million.

The company also raised guidance for its full fiscal year, and said it expects to report revenue between $564.6 million and $565.6 million, up from the range the company shared last quarter, when it expected $535 million to $540 million. Analysts were expecting $540 million for the year.

“We’re proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools,” Doximity CEO Jeff Tangney said in a statement. “Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers.”

The company reported net income of $75.2 million, or 37 cents per share, during its third quarter, up from $48.0 million, or 24 cents per share, a year prior. Doximity’s adjusted EBITDA was $102.0 million, up 39% year over year.

Doximity has been a bright spot within the battered digital health sector, which has faced a reckoning as companies have had to adjust to a more muted growth environment. The company’s stock price more than doubled in 2024.

Don’t miss these insights from CNBC PRO



Source

Buying chip stocks is getting pricey. Traders don’t care
World

Buying chip stocks is getting pricey. Traders don’t care

Intel Xeon 6 processors are shown to CNBC at Intel’s advanced packaging facility in Chandler, Arizona, on November 17, 2025. Tony Puyol Semiconductors are a runaway train — up 17 of the past 18 sessions — and options traders are buying increasingly expensive call options to chase the rally higher. The VanEck Semiconductor ETF (SMH) […]

Read More
The charts are showing there’s more pain ahead for healthcare stocks, says Carter Worth
World

The charts are showing there’s more pain ahead for healthcare stocks, says Carter Worth

(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) The worst performing sector year to date is healthcare, and there is every indication there is more downside ahead. The 2-panel chart below tells the tale. The top panel is the Health Care Select Sector SPDR ETF (XLV) itself, and it is a bad […]

Read More
Intel’s stock soars more than 20% as chipmaker shows signs of a turnaround
World

Intel’s stock soars more than 20% as chipmaker shows signs of a turnaround

The Intel logo is displayed on a sign in front of Intel headquarters on Jan. 22, 2026 in Santa Clara, California. Justin Sullivan | Getty Images Intel shares soared more than 20% on Friday as investors cheered signs of renewed growth due to mounting artificial intelligence demand. The stock was up 22% as of early […]

Read More